BioAtla (BCAB) Total Non-Current Liabilities (2020 - 2026)
BioAtla (BCAB) posted quarterly Total Non-Current Liabilities of $45.0 million for Q1 2026, up 25.75% year-over-year from $35.8 million in Q1 2025, and down 3.16% quarter-over-quarter from $46.5 million in Q4 2025.
BioAtla (BCAB) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
BioAtla's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $45.0 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 25.75% year-over-year to $45.0 million; the TTM figure through Mar 2026 stood at $45.0 million (up 25.75% YoY), while the FY2025 annual figure was $46.5 million, up 153.4% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $45.0 million, down from $46.5 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $49.0 million in Q4 2023, with the low at $17.5 million in Q2 2024.
- The 5-year median for Total Non-Current Liabilities is $28.3 million (2023), against an average of $30.7 million.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities plunged 62.54% in 2024, then jumped 153.4% in 2025.
- BioAtla's Total Non-Current Liabilities stood at $25.6 million in 2022, then soared by 91.42% to $49.0 million in 2023, then slumped by 62.54% to $18.4 million in 2024, then surged by 153.4% to $46.5 million in 2025, then fell by 3.16% to $45.0 million in 2026.
- Business Quant data shows BCAB's Total Non-Current Liabilities at $45.0 million in Q1 2026, $46.5 million in Q4 2025, and $27.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | BioAtla | 5.28 Mn | 5.28 Mn | - | 25.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.94 Mn |
| Mar 31, 2026 | 45.03 Mn |
| Dec 31, 2025 | 46.50 Mn |
| Sep 30, 2025 | 27.34 Mn |
| Jun 30, 2025 | 41.65 Mn |
| Mar 31, 2025 | 35.81 Mn |
| Dec 31, 2024 | 18.35 Mn |
| Sep 30, 2024 | 19.46 Mn |
| Jun 30, 2024 | 17.46 Mn |
| Mar 31, 2024 | 19.68 Mn |
| Dec 31, 2023 | 48.99 Mn |
| Sep 30, 2023 | 36.85 Mn |
| Jun 30, 2023 | 35.32 Mn |
| Mar 31, 2023 | 28.32 Mn |
| Dec 31, 2022 | 25.59 Mn |
| Sep 30, 2022 | 26.67 Mn |
| Jun 30, 2022 | 28.74 Mn |
| Mar 31, 2022 | 20.79 Mn |
| Dec 31, 2021 | 23.80 Mn |
| Dec 31, 2020 | 34.96 Mn |